Quick Answer
Oruka Therapeutics, Inc. reported Operating Income Loss of -$122.05 million for the year ending 2025.
- Oruka Therapeutics, Inc. showed a decrease of -38.5% in Operating Income Loss from 2024 to 2025.
- This data is from Oruka Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), Oruka Therapeutics, Inc.'s Operating Income Loss has declined by 1,230.3%.
- Historical annual values: Fiscal year 2025: -$122.05 million | Fiscal year 2024: -$88.12 million | Fiscal year 2023: -$7.30 million | Fiscal year 2022: -$10.60 million | Fiscal year 2021: -$19.34 million | Fiscal year 2020: -$9.77 million | Fiscal year 2019: -$5.81 million | Fiscal year 2018: -$8.12 million | Fiscal year 2017: -$18.71 million | Fiscal year 2016: -$16.61 million | Fiscal year 2015: -$11.46 million | Fiscal year 2014: -$9.69 million | Fiscal year 2013: -$6.94 million | Fiscal year 2012: -$4.32 million | Fiscal year 2011: -$7.36 million | Fiscal year 2010: -$9.18 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: